TRANSFORMED NON-HODGKIN LYMPHOMA
Clinical trials for TRANSFORMED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells aim to stop lymphoma return after transplant
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or returning lymphoma will receive the treatment. The…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New hope for lymphoma patients: drug cocktail aims to control cancer without transplant
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can better control relapsed or refractory large B-cell lymphoma in people who are not eligible for a stem cell transplant. About 227 participants will…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New CAR T-Cell therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis trial tests a new CAR T-cell therapy called WZTL-002 in 60 people with large B-cell lymphoma that has returned or not responded to standard chemotherapy. Participants receive their own modified immune cells to attack the cancer, and doctors will check how many achieve comple…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New combo therapy aims to keep lymphoma in check after transplant
Disease control Recruiting nowThis study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…
Matched conditions: TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 22, 2026 14:03 UTC